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ABSTRACT
The current COVID-19 pandemic presents a serious public health crisis, and a better understanding of the scope and
spread of the virus would be aided bymorewidespread testing. Nucleic-acid-based tests currently offer themost sensitive
and early detection of COVID-19. However, the “gold standard” test pioneered by the U.S. Centers for Disease Control
and Prevention takes several hours to complete and requires extensive human labor, materials such as RNA extraction
kits that could become in short supply, and relatively scarce qPCR machines. It is clear that a huge effort needs to be
made to scale up current COVID-19 testing by orders of magnitude. There is thus a pressing need to evaluate alternative
protocols, reagents, and approaches to allow nucleic-acid testing to continue in the face of these potential shortages.
There has been a tremendous explosion in the number of papers written within the first weeks of the pandemic evaluating
potential advances, comparable reagents, and alternatives to the “gold-standard” CDC RT-PCR test. Here we present a
collection of these recent advances in COVID-19 nucleic acid testing, including both peer-reviewed and preprint articles.
Due to the rapid developments during this crisis, we have included as many publications as possible, but many of the cited
sources have not yet been peer-reviewed, so we urge researchers to further validate results in their own laboratories. We
hope that this review can urgently consolidate and disseminate information to aid researchers in designing and implement-
ing optimized COVID-19 testing protocols to increase the availability, accuracy, and speed of widespread COVID-19
testing.
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OVERVIEW
On March 11th, 2020, the World Health Organization
deemed COVID-19 a global pandemic (World Health
Organization 2020). As of April 26th, SARS-CoV-2 infec-
tions have been confirmed in almost 3 million people
worldwide, yet even this staggering figure is likely to be
an underestimate (Elflein 2020). To have any actionable
impact on our control of the pandemic propagation, tests
should be performed repetitively on a large fraction of the
population in order to detect outbreaks before they
spread. Current estimates of the testing capacity needed
to end the pandemic are in the range of tens of millions
of tests per day in the U.S., far above the ∼145,000 tests
currently conducted nationally (Goodnough et al. 2020;
Irfan 2020). A solution to massively scaling up COVID-19
testing by orders of magnitudes may be aided by an inno-
vative combination of the molecular tools presented here.
Current testing approaches fall into two categories—nu-
cleic-acid or serological. Nucleic-acid tests directly probe
for the RNA of viruses swabbed from a patient’s throat or
nasal passage (Fig. 1), while serological tests detect anti-
bodies present in the patient’s serum. During the first
days of infection, patient viral titers are high and a single
patient nasopharyngeal swabmay harbor close to 1million
SARS-COV-2 viral particles (Wölfel et al. 2020). However,
patient IgG and IgM antibody production, termed sero-
conversion, typically occurs 5–10 d after the onset of initial
symptoms (Wölfel et al. 2020). Therefore, nucleic acid tests
offer the earliest and most sensitive detection for the pres-
ence of SARS-COV-2 and will be the subject of this review.
The RT-PCR test pioneered by the CDC has been deemed
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the “gold standard” for clinical diagnosis but takes hours
to perform and requires specialized reagents, equipment,
and training (Centers for Disease Control and Prevention
2020). In the first fewweeks of the global SARS-CoV-2 pan-
demic, required reagents were already in short supply, and
researchers and testing centers reported issues acquiring
almost every necessary reagent from commercial suppli-
ers—from patient nasopharyngeal swabs to lysis buffer to
RNA extraction kits (Akst 2020; Baird 2020). Some testing
centers have even been running multiple testing protocols
side-by-side to increase throughput and allow for de-
creased reliance on a single reagent (Soucheray 2020). A
few commercial test systems exist but are primarily de-
signed to give single-patient results (Abbott 2020; Xpert
Xpress SARS-CoV-2, https://www.fda.gov/media/136314/
download). A scalable, high-through-
put platform will be required to
deliver millions of tests per day. Here
we investigate recent advances and
approaches to nucleic-acid testing
for COVID-19. We highlight some
findings from research groups who
have compared commercial reagents
or created homemade solutions in
order to decrease cost or reliance
on particular commercial reagents.
We also outline several alternative
nucleic-acid tests involving isothermal
amplification or CRISPR-based detec-
tion. Finally, we examine some recent
applications of specialized techniques
such as sequencing, digital PCR, and
DNA nanoswitches as tools for
COVID-19 detection. We have tried
to be as exhaustive as possible
throughout this review, but due to
the rapid daily developments in test-
ing wemay have unwittingly excluded
some published works. Another re-
view by Shen et al. (2020) published
in late Februarymay be useful to read-
ers. In this review, we greatly expand
the scope to evaluate and compare
many more recently published arti-
cles, address advancements in sam-
ple lysis, direct addition, and novel
detection methods, and include a
quantitative comparison of these
methods including workflow time,
cost, and limit of detection.
The general workflow for RT-PCR
tests, such as that approved by the
CDC, includes three main steps: sam-
ple collection and transport, lysis and
RNA purification, and amplification
(Fig. 2). Typically, a clinician collects a nasopharyngeal
swab and transfers it to a vial containing a few milliliters
of viral transport medium (VTM), which is transported to
a laboratory for testing. Chemical lysis buffers or heating
may be used to lyse and inactivate viral particles. The viral
RNA is then purified from a fraction of the swab sample
(typically 1/20th of the swab) using column-based RNA pu-
rification kits or magnetic beads. The eluted purified RNA
is then amplified using a one-step master mix containing
reverse transcriptase and DNA polymerase enzymes with
three primers targeting specific regions of the viral ge-
nome. Primers targeting a human gene, such as RNaseP,
are also included as a positive control for swab collection,
RNA extraction and amplification. A spike-in control
RNA, such as MS2 bacteriophage genomic RNA, may
FIGURE 1. An overview of COVID-19 nucleic acid testing. Samples collected via nasopharyn-
geal swab are lysed and inactivated, and an amplification reaction is performed using either a
crude swab sample or purified RNA. Amplification of specific viral sequences by RT-PCR,
LAMP, or RPA is detected using fluorescent or colorimetric dyes, sequence-specific CRISPR-
Cas nuclease cleavage of a reporter, or separation of reaction products on a lateral flow
dipstick.
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alternatively be used. Amplified products can be detected
using TaqMan probe fluorescence or DNA-intercalating
dyes, and a threshold cycle of amplification is set to distin-
guish positive from negative results. A test result is typical-
ly considered positive if amplification is observed for two
or more viral targets, while it is considered negative if
amplification is observed for the control RNA but for
none of the viral targets (Centers for Disease Control and
Prevention 2020).
The standard CDC RT-PCR test takes about 3 h to per-
form and costs ∼$10 per test (Supplemental Table S1).
Specialized reagents or equipment can lead to high per-
test costs and may limit the number of tests that can be
conducted, in some cases resulting in a lag of several
days before a patient receives a diagnosis. The variety of
approaches presented here span a wide range of costs
and processing times, with several published protocols
reaching results in less than 1 h (Fig. 3). Some investigators
have found homemade solutions that drastically decrease
the required reagent cost allowing for tests to be per-
formed for just a few dollars (Supplemental Table S2).
Others have proposed completely novel solutions that
can cut the testing time to tens of minutes but may still re-
quire costly reagents to perform.While widespread testing
will necessarily require high-throughput approaches, other
tests may offer higher sensitivity for low titer cases or rapid
turnaround for point-of-care diagnosis. Recent ingenuity in
COVID-19 nucleic-acid testing offers a wide range of solu-
tions and further innovation may be required to maximize
testing accuracy while providing a low-cost and fast-turn-
around solution.
SAMPLE LYSIS AND DIRECT ADDITION
Testing for the presence of SARS-CoV-2 viral RNA typically
begins with the collection of a patient swab sample which
is stored and transported to a testing facility in viral trans-
port medium (VTM). These samples are lysed and viral
RNA is typically purified using either RNA extraction col-
umns or magnetic beads (Fig. 2; Centers for Disease
Control and Prevention 2020). One advantage of RNA pu-
rification is that the viral RNA present
in the more dilute swab sample can
be concentrated and eluted in a buff-
er compatible with RT-PCR. However,
in order to decrease reliance on com-
mercial lysis buffers and viral RNA ex-
traction kits and simplify COVID-19
testing, there has been great interest
in finding alternative strategies or
eliminating RNApurification altogeth-
er by adding patient swab samples
directly to the RT-PCR reaction.
Additionally, eliminating RNA purifi-
cation can dramatically speed up the overall workflow
time per test and may be an ideal solution for streamlining
testing times (Fig. 4).
Swab samples must be lysed to release viral RNA into
solution for purification and to neutralize the virus for
safe handling. Many protocols use commercial reagents
for lysis, including DNA/RNA Shield (Zymo Research),
Buffer RLT (Qiagen), and MagNA Pure External Lysis
Buffer (Roche). However, multiple researchers have recent-
ly found that when compared to commercial solutions,
homemade solutions containing 4M (Scallan et al. 2020;
Sridhar et al. 2020) or 5M (Aitken et al. 2020) guanidinium
thiocyanate work equally well to lyse samples and recover
viral RNA after purification. However, these solutions con-
tain strong denaturants and are therefore not compatible
with addition directly into amplification reactions. Other
laboratories have assessed lysis conditions that are com-
patible with direct addition in order to streamline sample
preparation and reduce overall test time. Preliminary
FIGURE 3. An analysis of the total workflow time and calculated cost
(in U.S. dollars) of published COVID-19 nucleic acid tests. Calculated
costs are estimated from available online pricing for consumables and
do not include labor or equipment. Protocols which required key re-
agents to be synthesized or created in a laboratory are not included
but are likely to be even cheaper than commercially priced reagents.
All raw data available in Supplemental Tables S1, S2.
FIGURE 2. An overview of sample processing. Patient nasopharyngeal swabs are collected
and transported for testing. Viral particles are inactivated and lysed by heat and/or lysis buffer
addition. Swab sample is then added directly to amplification reactions or RNA is purified from
the sample and then amplified.
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studies report that direct-to-test addition of unprocessed
swab samples generally allows for SARS-CoV-2 detection
but may decrease test sensitivity. Viral RNA stability and
compatibility with downstream reactions will be heavily
dependent on the buffer used for swab collection and
transport. Arumugam and Wong have shown that RNA
can be detected from nonreplicative recombinant virus
particles (SeraCare AccuPlex) in VTM spiked directly into
the RT-PCR master mix without an RNA extraction step
(Arumugam and Wong 2020). Merindol et al. (2020) com-
pared a few common swab collection buffers for compati-
bility with direct PCR addition. Swab samples stored in
Hank’s medium or saline solution and directly added to
RT-PCR reactions amplified poorly using either the
RealStar SARS-CoV-2 RT-PCR kit (Altona Diagnostics) or
the Allplex 2019-nCoV RT-QPCR kit (Seegene) compared
to purified RNA from the same swabs. Interestingly, how-
ever, viral RNA added directly from swabs stored in water
or UTM (Remel) at 4°C showed equivalent RT-PCR amplifi-
cation to RNA purified from the same swabs. In the pres-
ence of RNase inhibitor, viral RNA could be amplified
with similar efficiency from swabs stored in water at 4°C
for up to 5 d (Merindol et al. 2020).
Many groups are further optimizing direct-to-test addi-
tion by heating and/or lysing swab samples prior to testing.
In one study, direct addition of swab samples in viral trans-
port media to the Luna Universal ProbeOne Step RT qPCR
master mix (New England Biolabs) accurately identified
92% of 155 COVID-19 cases but reached the detection
threshold four cycles later (corresponding to a 16-fold
loss in detection of starting material) than a test using
RNA extracted from a swab sample using theQIAamp Viral
RNA Mini kit (Qiagen) (Bruce et al. 2020). This procedure
could correctly identify cases across low, medium, or high
SARS-CoV-2 RNA copy loads (as defined by cycles to
detection from tests of the same samples after RNA purifi-
cation). Heating the swab sample at 95°C for 10min before
direct-to-test addition improved detection of low copy
load samples (Bruce et al. 2020). Another group reported
that directly added samples were detected 3.5 cycles later
than RNA isolated using the MagNA Pure kit (Roche), but
heating the sample at 95°C for 5 min before direct-to-test
addition resulted in detection only one cycle later, with
97.4% accuracy compared to tests using purified RNA
(Fomsgaard and Rosenstierne 2020). However, Grant
et al. (2020) found the opposite—heating direct-to-test
samples in VTM at 95°C for 10min delayed detection of vi-
ral RNA compared to directly added samples not heated
prior to amplification. Additionally, they found that direct
sample addition in VTM without heating to the TaqMan
Fast Virus 1-stepMasterMix (ThermoFisher) RT-qPCR reac-
tion allowed detection 3.77 cycles earlier than the same
test performed with RNA purified using the EZ1 Qiagen
kit. Overall, their test using a direct, unheated sample
had 98.8% diagnostic accuracy when compared to car-
tridge-based RNApurification and RT-qPCR using the Pan-
ther Fusion system (Grant et al. 2020). Intermediate
inactivation temperatures seem to perform worse than
high heat or no heating at all. One group reported that
swab sample heat treatment at 75°C for 10 min prior to di-
rect-to-test addition delayed detection by 6.1 cycles
(Alcoba-Florez et al. 2020). Multiple groups have reported
contradictory findings on the advantages of heating sam-
ples before direct addition into RT-PCRmixes. RNases pre-
sent in the nasal swab are likely active even at high
temperatures and thus RNA degradation may be particu-
larly sensitive to the temperature and buffer conditions of
inactivation.
Slightly more complex approaches use lysis buffers to
aid RNA recovery and improve RT-qPCR test sensitivity.
In one report, positive patient swab samples diluted 1:1
into Quick Extract DNA extraction solution (a buffer con-
taining detergents and proteinase K), heat inactivated
and directly added to the RT-PCR reaction mix were de-
tected at the same amplification cycle as, or even slightly
before, samples processed with the QIAmp Viral RNA
Miniprep kit (Qiagen) (Ladha et al. 2020). Another group
reported that swab samples added to Quick Extract DNA
extraction solution were detected with equal sensitivity
to column-purified RNA (Sentmanat et al. 2020). Finally,
another study reported that direct addition of swab sam-
ples treated 15 min with proteinase K yielded sensitivity
comparable to the use of RNA isolatedwith the automated
ELITe InGenius Sp200 system (ELITech Group) (Marzinotto
et al. 2020).
The discrepancy between the sensitivities of direct-to-
test addition procedures may be due to differences in pro-
tocols and kits used for the RT-qPCR test and isolation of
control RNA, types of lysis buffers, heating parameters,
and varying viral RNA loads in the swab samples of each
study. Despite these discrepancies, it appears that di-
rect-to-test addition of a small volume of swab sample
treated with lysis buffer or Proteinase K allows for robust
SARS-CoV-2 RNA detection. Direct-to-test addition of pa-
tient swab samples may prove useful in settings where
there is a lack of RNA purification reagents or time con-
straints that render laborious RNA isolations infeasible.
Further work is required to ascertain optimal swab sample
lysis, heating and storage conditions prior to direct-to test
addition, as well as whether direct-to-test addition could
be used in tests other than RT-qPCR.
RNA PURIFICATION
As uncovered by multiple groups, eliminating RNA isola-
tion prior to RT-PCR altogether may be possible.
However, a dedicated RNA isolation step may improve
detection sensitivity or be necessary to remove incompat-
ible sample buffers prior to amplification for some proto-
cols. However, column-based kits used to purify RNA
Esbin et al.
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from the patient swab sample can also occasionally lead to
unintentional carryover of ethanol or retention of some
RNA, which can be kit-specific. In our laboratory, we have
found that theRNeasyMini Kit (Qiagen) leads to an approx-
imately eightfold (3Ct) loss of synthesizedSARS-CoV-2 viral
N gene RNA after column purification.We found similar re-
sults with inactivated positive patient swab samples;Ct val-
ues were consistently lower when RNA was purified via
isopropanol precipitation or using the Direct-zol RNA
Miniprep Plus kit (Zymo Research) when compared to the
RNeasyMini Kit (Qiagen). However,wehavenot compared
directly with the CDC recommended Qiagen QIAmp Viral
RNA kit (C Dugast-Darzacq, T Graham, GM Dailey, et al.,
unpubl.). Several recent papers have investigated alterna-
tive methods for RNA purification, including unique ap-
proaches as well as traditional laboratory techniques.
Zhao et al. (2020) present a synthesis protocol for magnetic
nanoparticles that can combine sample lysis andRNAbind-
ing in a single step. The polyamino ester with carboxyl
groups-coated magnetic nanoparticles (pcMNPs) are also
directly compatible with the RT-PCR reaction, greatly
streamlining the protocol from lysis through RNA purifica-
tion, and the pcMNPs can be synthesized on-site. Kalikiri
et al. (2020) find that AmpureXP beads (Beckman Coulter)
yield equal sensitivity to theNucliSENS easyMAG automat-
edextractionplatform (bioMérieux).Other commonly used
laboratory reagents for RNA purification include TRIzol,
which includes guandinium thiocyanate and phenol-chlo-
roform to extract RNA from cellular samples. Won and co-
workers describe a complete workflow for COVID-19
testing which includes TRIzol extraction and isopropanol
precipitation of the RNA from swab samples. The authors
found no difference between TRIzol and the approved
Qiagen QIAamp Viral RNA Mini Kit in RNA extraction effi-
ciency from Lentivirus-infected HEK293 cells, but was not
directly compared using SARS-CoV-2 RNA (Won et al.
2020). In our laboratory, isopropanol precipitation of syn-
thesized SARS-CoV-2 viral N gene RNA resulted in almost
no loss of RNA, with or without the presence of additional
human RNA as a carrier (C Dugast-Darzacq, T Graham, GM
Dailey, et al., unpubl.). Standard laboratory RNA purifica-
tion methods offer an attractive alternative to commercial
FIGURE 4. Examination of the total workflow for published COVID-19 testing methods. Each step of the workflow is shown with colored bars.
Four example commercial RT-PCR kits are included for reference (blue) and were directly compared within a single publication. The CDC
RT-PCR test is shown in red. (∗) Sequencing typically takes 4–12 h but can vary significantly depending on library preparation and the platform
used, and was not specifically stated in the cited protocols. Raw data available in Supplemental Table S1.
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kits, as they generally use inexpensive, abundantmaterials.
For clinical testing, however, these solutions may be diffi-
cult to scale to high-throughput pipelines and may require
special handling of hazardousmaterials. It may be useful to
assess where RNAextraction canbe eliminatedwhilemain-
taining the necessary sensitivity and accuracy of testing. If
eliminating RNA purification is not possible, however,
these procedures could be useful as cheap, homemade so-
lutions for small-scale testing operations.
RT-PCR
RT-PCRmastermixes use amixture of reverse transcriptase
enzymes, such as the thermostable MMLV RT, and a DNA
polymerase, like Taq. Primers that anneal specifically to
theSARS-COV-2 viral genomeare included toprimeampli-
fication. The U.S. CDC protocol utilizes primers that target
the viralN gene, while the China CDC uses primers match-
ing both the N gene and the ORF1ab region, and Charité
Germany primers target the RdRp and E genes (for review,
see Udugama et al. 2020). For detection of amplification,
qPCR can be performed using intercalating dyes like Sybr-
Green. Because these dyes are nonspecific for DNA prod-
ucts, any amplification (specific or not) will lead to an
increased fluorescent readout. Higher sequence specificity
in the detection of amplicons can be achieved using Taq-
man probes. These short oligonucleotides contain a 5′ flu-
orophore and 3′ quencher and anneal to sequences within
the DNA template. Taq polymerase degrades the an-
nealedprobeby its 5′ to 3′ exonuclease activity and cleaves
off the fluorophore, thereby releasing it from being
quenched. This fluorescence is proportional to the number
of amplified product molecules, is sequence-specific for
the correct amplified product, and can be measured in
real-time on a qPCR machine (Fig. 5).
RT-PCR has been deemed the “gold standard” for
COVID-19 diagnosis because it has shown to be very sensi-
tive for accurately detecting viral genomes present, down to
just onemolecule of RNA (Fig. 6). Multiple commercial mas-
ter mixes exist that enable sensitive one-step RT-PCR. The
original CDC protocol approved four commercial master
mixes for the RT-PCR test from Quantabio, Promega, and
ThermoFisher (Centers for Disease Control and Prevention
2020). However, published RT-PCR protocols have also suc-
cessfully used one-step RT-PCRmaster mixes from a variety
of companies includingNEB, Applied Biosciences, Qiagen,
Roche, Takara, andothers, and agrowing list of approvedal-
ternative commercial reagents canbe foundat theFDAEUA
website (Alcoba-Florez et al. 2020; Chandler-Brown et al.
2020; Food and Drug Administration 2020; Kalikiri et al.
2020; Marzinotto et al. 2020; Merindol et al. 2020; Won
et al. 2020; Xu et al. 2020; Zhao et al. 2020). Many commer-
cial master mixes seem to function well in the detection of
SARS-CoV-2, although a detailed side-by-side comparison
of the numerous commercial reagents is lacking. Brown
et al. (2020) compared four popular one-step RT-PCR kits
(Takara One Step PrimeScript III kit, QiagenQuantifast Mul-
tiplex RT-PCR+RMasterMix, ThermoFisher TaqPath 1-step
RT-qPCR Master Mix, and the Thermo Fisher Taqman Fast
Virus 1-step Master Mix) on 74 patient nose and/or throat
swabs. Comparison of the four master mixes showed that
three out of the four mixes performed optimally with the
N2primers for SARS-CoV-2 detection—the Takara,Qiagen,
and TaqPath. The best, however, seemed to be the Takara
master mix, which was able to detect just a single viral ge-
nomecopyusing theN1primers. Consistentwith theTakara
mix being the most sensitive, none of their patient samples
that tested negativewith the Takaramix tested positive with
theQiagenkit,whereas the reversedidnothold (Brownetal.
2020).
Additionally, in order to decrease reliance on a particu-
lar company to generate master mix reagents for testing,
FIGURE 5. Molecular overview of the RT-PCR reaction. Taqman
probes are used to visualize increased fluorescence during each cycle
of amplification. Amplification is quantified by Cq readout and a
threshold is set for positive detection of the target amplicon.
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which in the course of the pandemic could experience sup-
ply chain disruptions or delays, at least one laboratory has
developed a completely homemade, open-source master
mix. Bhadra et al. have developed master mixes using the
evolved reverse transcriptase/DNA polymerase RTX that
are compatible both with either dye-based or TaqMan
qPCR. The RTX enzyme can be expressed in E. coli and pu-
rified using Ni-NTA agarose and heparin columns, and
master mix buffers can be made easily and cheaply in a
laboratory. The authors demonstrated detection of as
few as 100 molecules of in vitro transcribed SARS-CoV-2
N gene RNA, using either RTX enzyme alone in a dye-
based reaction or a mixture of RTX and Taq in a TaqMan
reaction. TaqMan reactions with RTX and Taq showed
Cq values comparable to the commercial TaqPath kit
(Bhadra et al. 2020). Future studies should assess home-
mademastermixes using patient samples, to provide inex-
pensive, open-source options for testing.While a variety of
commercial and laboratory options exist for RT-PCR mas-
ter mixes, active enzymes typically require careful refriger-
ation for storage and transport. Xu et al. (2020) have
demonstrated that the Takara RT-PCR mix maintains its
activity after being freeze-dried and stored at room tem-
perature for 28 d. Further innovation in homemade or
room-temperature stable reagents may improve testing
capabilities in remote locations or at the point-of-care.
ISOTHERMAL AMPLIFICATION
A promising alternative to RT-PCR is isothermal amplifica-
tion, which does not require thermocycling. Two isother-
mal techniques used for rapid and sensitive diagnostics
are loop-mediated isothermal amplification (LAMP) and
recombinase polymerase amplification (RPA) (Fig. 7).
LAMP uses a strand-displacing DNA polymerase together
with four specially designed primers containing regions of
complementarity to six target sequences. The 3′ end of the
forward inner primer (FIP) primes synthesis of an initial
DNA strand, which is subsequently displaced by synthesis
primed by the forward outer primer (FOP). A reverse-com-
plementary sequence in the 5′ end of the FIP anneals with
a downstream sequence in the displaced ssDNA strand,
forming a loop. The same process repeats with the back-
ward inner and outer primers (BIP and BOP) at the oppo-
site end of the amplicon. Repeated rounds of priming
and strand extension generate a mixture of stem–loop
and “cauliflower” structured products. Because LAMP in-
cludes primers that anneal to six unique target regions, it
is highly sequence specific (Notomi et al. 2000). Release
of hydrogen ions upon incorporation of dNTPs into the na-
scent DNA chain can be detected using colorimetric pH
FIGURE 6. The limit of detection for published tests equivalent to the
fewest number of molecules accurately assayed in a single reaction.
For some spike-in controls, authors used viral DNA, plasmid DNA,
or a pseudovirus instead of viral RNA (shown as open diamonds),
which may have a different amplification efficiency than SARS-CoV-2
RNA and thus alter their calculated limit of detection. Raw data avail-
able in Supplemental Table S1.
FIGURE 7. Molecular overview of isothermal amplification tech-
niques. LAMP uses specially designed nested primers with comple-
mentary regions that form hairpins to permit priming of subsequent
rounds of amplification. RPA uses recombinase-catalyzed strand inva-
sion to prime amplification. Colorimetric pH indicators can be used to
detect hydrogen ion release during dNTP incorporation.
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indicator dyes (Tanner et al. 2015). RT-LAMP has been val-
idated for detection of a multitude of RNA viruses includ-
ing influenza, Zika, Ebola, and MERS (for review, see
Wong et al. 2018).
A slightly more recent addition to the isothermal ampli-
fication toolkit is RPA. RPA uses a recombinase to catalyze
strand invasion of a primer into dsDNA. Single-stranded
binding proteins are included to stabilize the open duplex
structure and a strand-displacing DNA polymerase ex-
tends the primer (Piepenburg et al. 2006). Some groups
have demonstrated very high sensitivity and specificity of
target amplification by combining RPA and LAMP into a
two-stage amplification protocol, termed RAMP. The outer
LAMP primers can be used for RPA amplification and then
combined with the additional LAMP primers for further
amplification in a single tube or microfluidic device. The
combined RAMP approach exhibits the extremely high
specificity of LAMP, together with enhanced sensitivity
from dual amplification, and a higher tolerance to inhibi-
tors (Song et al. 2017). Song et al. (2017) demonstrated
the huge potential of the RAMP approach for diagnostics
by multiplexing 16 pathogenic targets including HIV-1
and multiple strains of HPV ZIKV. These isothermal meth-
ods are relatively fast and can be read out colorimetrically,
with a lateral-flow stick, or even with nanoparticle-based
biosensors (Zhu et al. 2020), making them easy to use at
home or at remote points of care.
Several groups have now developed novel isothermal
protocols for detection of SARS-COV-2 RNA. Lu et al.
(2020b) tested their LAMP-based detection method with
spiked-in SARS-COV-2 RNA and were able to detect a col-
orimetric change indicating a positive result after just 40
min of amplification, with sensitivity down to 30 viral
RNA copies per reaction. They and others have demon-
strated that LAMP detection of SARS-CoV-2 is specific by
showing no cross-reactivity to other respiratory pathogens
including human coronavirus strains HCoV-OC43 and
HCoV-229E (Lu et al. 2020b; Park et al. 2020). Zhang
et al. have shown that their LAMP strategy gives results
that match the RT-PCR standard test in COVID-19 positive
patient samples, reporting 100% sensitivity and specificity.
They also find that the LAMP protocol may be compatible
with cell lysates, potentially eliminating the need for RNA
purification from patient samples (Zhang et al. 2020a).
Using 130 samples, Yan et al. were able to directly com-
pare RT-PCR with RT-LAMP. The LAMP assay gave identi-
cal clinical diagnoses to the RT-PCR test, with similar
sensitivity, and it was faster and easier to read out (Yan
et al. 2020). Others have reported similar success, with
LAMP amplification yielding 90%–100% sensitivity and
95%–99% specificity in patient samples with improved ac-
curacy for amplification of multiple gene targets (Jiang
et al. 2020; Mehmood Butt et al. 2020; Yang et al. 2020;
Yu et al. 2020). A smaller cohort study found that their
RT-LAMP test had a sensitivity of 80%, compared to con-
secutive RT-PCR swabs, which could be adequate clinical-
ly, they suggest, if repeated testing were used (Österdahl
et al. 2020). By combining two common isothermal tech-
niques, LAMP and RPA, into a single-tube RAMP reaction,
El-Tholoth and colleagues were able to improve detection
100-fold over RT-PCR in mimic patient samples, providing
an early proof-of-concept for an extremely sensitive meth-
od that can detect down to just a few viral RNA copies, but
that to date has not yet been tested on patient samples (El-
Tholoth et al. 2020). From these early demonstrations, un-
der optimized conditions isothermal amplification tech-
niques can provide equal sensitivity and specificity to the
RT-PCR test for SARS-CoV-2 detection. These methods al-
low for faster amplification, less specialized equipment,
and easy readout. LAMP methods also benefit from the
ability to multiplex targets in a single reaction and can
be combined with other isothermal methods, like RPA in
the RAMP technique, to increase test accuracy even
more. These techniques may be particularly useful for rap-
id, point-of-care diagnoses or for remote clinical testing
without the need for laboratory equipment.
CRISPR-BASED DETECTION
A unique group of Cas nucleases, including Cas12 and
Cas13 were recently discovered to have promiscuous
DNA or RNA cleavage activities (Gootenberg et al. 2017;
Chen et al. 2018; Li et al. 2018), which have been exploited
for nucleic acid detection. Multiple assays combining iso-
thermal amplification and CRISPR have recently emerged
as diagnostic tools for rapid detection of SARS-CoV-2 viral
RNA (Fig. 8).
Cas13a is a nonspecific RNase that remains inactive until
it binds its programmed RNA target. It has been harnessed
for sensitive DNA or RNA detection in a method termed
SHERLOCK (Gootenberg et al. 2017) In SHERLOCK, the
target RNA is first amplified by a combination of RT-RPA
and T7 transcription. The amplified product RNA activates
Cas13a, which in turn cleaves a reporter RNA, liberating a
fluorescent dye from a quencher. This method consistently
detects synthetic SARS-CoV-2 viral RNA in the range be-
tween 10 and 100 copies per µL of input, only requires a
lateral flow dipstick for visual readout of the detection re-
sult, and can be completed in 40 min (Hou et al. 2020) or
57 min (Metsky et al. 2020; Zhang et al. 2020b) after the
RNA extraction step. SHERLOCK (termed “CRISPR-
nCoV” in Hou et al. 2020) also demonstrated its diagnostic
potential by detecting SARS-CoV-2 RNA with 100% sensi-
tivity in 52 patient samples (Hou et al. 2020).
Cas12 is another member of the CRISPR-Cas effector
family. It is an RNA-guided DNase that indiscriminately
cleaves ssDNA upon binding its target sequence. In a
method termed “DETECTR,” Cas12a ssDNase activation
is combined with isothermal amplification to achieve sen-
sitive and specific DNA detection (Chen et al. 2018).
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Multiple groups have recently used DETECTR for SARS-
CoV-2 RNA detection. Viral RNA is first converted to
DNA and isothermally amplified. Specific target sequenc-
es in the amplified DNA activate Cas12a, which in turn
cleaves a ssDNA reporter to unquench a fluorophore.
Using RT-RPA for amplification in DETECTR, Lucia et al.
(2020) detected 10 copies of SARS-CoV-2 RNA per µL of
input within 60 min (after RNA sample preparation). Ding
et al. improved the protocol by combining RT-RPA and
CRISPR-based detection in a one-pot reaction and incu-
bating at a single temperature. This “All-In-One Dual
CRISPR-Cas12a” (AIOD-CRISPR) assay detected as few
as 4.6 copies of SARS-CoV-2 RNA per µL of input in
40 min (Ding et al. 2020). Similarly, Guo et al. developed
another single-tube and constant temperature protocol
(“CDetection”), in which they used recombinase-aided
amplification (RAA) instead of RPA for nucleic acid amplifi-
cation. They showed that Cas12b behaves similarly to
Cas12a for ssDNA reporter cleavage and can achieve a
detection limit of five copies/µL in 40–60 min (Guo et al.
2020). Moreover, Broughton et al. used LAMP instead of
RPA in DETECTR and further reduced the testing time
for SARS-CoV-2 RNA to 30–32 min while maintaining a
low detection limit (10 copies/µL) (Broughton et al. 2020).
In combination with fast isothermal amplification,
CRISPR-based techniques can harness highly specific nu-
cleases to achieve fast read-outs and sensitivity down to
a few viral RNA copies. CRISPR detection can be coupled
to lateral flow readouts, which are an attractive option for
easy, at-home testing scenarios.
SEQUENCING FOR DIAGNOSIS
Sequencing-based detectionmethods provide the benefit
of collecting base-pair-level information of patient strains,
which allows for viral mutation tracing but comes at the
cost of expensive sequencing platforms and lengthy sam-
ple processing times. However, several laboratories have
investigated high-throughput approaches or portable,
fast sequencing to use this technology as a diagnostic
tool for COVID-19. Nanopore target sequencing (NTS) is
an attractive option for clinical testing because it is fast,
highly portable, and sensitive.Wang et al. have developed
an NTS approach targeting 11 viral regions that is able to
detect as few as 10 viral copies/mL with 1 h of sequencing.
By relying on a sequencing-based approach, this group
also demonstrated that viral genome mutations can be
identified within the target regions, and that an additional
panel of targets against common respiratory viruses can be
included to detect co-infection (Wang et al. 2020). Addi-
tionally, commercial sequencing approaches have also
been adapted for high-throughput SARS-CoV-2 testing.
BillionToOne Inc. seeks to use the extensive national infra-
structure for Sanger sequencing, which they propose could
“unlockmore than1,000,000 tests per day in theUS” (Chan-
dler-Brown et al. 2020). BillionToOne uses a one-step RT-
PCR mix to amplify viral RNA directly from swab samples,
which are collected in viral transport medium rather than a
custom lysis buffer. Sanger sequencing then proceeds
with inclusion of a synthetic, shortened SARS-CoV-2 se-
quence as a spike-in control allowing for careful quantitation
of viral abundancedownto∼10genomicequivalents (Chan-
dler-Brown et al. 2020). While traditional sequencing ap-
proaches typically require substantial cost and
specialization, repurposed portable or quantitative se-
quencing approaches may offer extremely accurate high-
throughput diagnostics during the pandemic.
OTHER NATs (“THINKING OUTSIDE THE BOX”)
Beyond the approaches described above, ingenious meth-
ods are being developed for widespread, at-home, or
point-of-careCOVID-19diagnostics.Most isothermal ampli-
fication steps require incubation at elevated temperatures
around60°C. To facilitate isothermal amplificationat remote
FIGURE 8. Molecular overview of CRISPR detection of amplified
products. Binding to specific target sequences in amplified RNA or
DNA activates Cas nucleases, which cleave reporter molecules.
Reporter cleavage can then be assayed using a lateral dipstick.
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testing facilities, González-González et al. (2020) developed
a 3D-printed water circulator that can act as a heat block for
LAMP amplification and have demonstrated the ability to
detect as few as 62 viral RNA molecules after 1 h of incuba-
tion. To make RT-PCR more accessible for remote testing,
Wee et al. (2020) have demonstrated a rapid, extraction-
free PCR protocol that can detect six SARS-CoV-2 RNA cop-
ies using a portable thermocycler.
While samples collected from patients with symptoms
or who have been hospitalized seem to present relatively
high viral titers that are likely to be easier to detect (Wölfel
et al. 2020), testing of asymptomatic patients or testing
prior to quarantine release may require extremely sensi-
tive tests. While specialized reagents and equipment are
required, digital and digital-droplet PCR may allow for
even more sensitive testing than RT-PCR. Lu et al.
(2020a) report 96.3% accuracy for testing of clinical sam-
ples using digital PCR and were able to detect virus in
four patient samples that were deemed negative by RT-
PCR. Furthermore, digital droplet methods have been
shown to be capable of detecting down to 0.4 viral RNA
copies/μL in patient samples (Suo et al. 2020). Because
digital PCR allows for more careful quantitation of
viral RNA copy number over the course of the disease,
this highly sensitive test may also be useful to evaluate
treatment progress or assess patient release after
quarantine.
Particularly as testing becomes more widespread, test-
ing of the general population and asymptomatic individ-
uals may lead to a large number of negative samples and
a huge increase in the demand of testing supplies. In an
innovative effort to further conserve resources using exist-
ing testing methodologies, some groups have investigat-
ed pooling many patient samples to decrease the
number of tests required for larger populations.
Proposed pooling approaches can be adaptive, where
samples are first pooled and tested and positive pools
are retested individually. This is a relatively simple solu-
tion which decreases overall testing resources used but
may introduce several disadvantages, including longer
wait times for results since positive samples must be iter-
atively tested, and a slight loss in sensitivity from diluting
positive patient samples with negative ones. Multiple
groups have modeled patient pooling and proposed al-
gorithms that optimize positive sample detection and
testing efficiency (Noriega and Samore 2020; Sinnott-
Armstrong et al. 2020). Some simple approaches like
pooling the rows and columns of a 96-well plate during
testing can increase efficiency four- to eightfold for low
prevalence populations (Sinnott-Armstrong et al. 2020).
Random pooling has also been shown to be useful for es-
timating disease prevalence and transmission within a lo-
cal area (Hogan et al. 2020). More complicated pooling
assignments and nonadaptive approaches have been
proposed and may significantly increase efficiency and al-
low for single-iteration pooled testing, but may be more
difficult to implement with common clinical workflows
and robotic pipetting (Täufer 2020). The solution to wide-
spread testing is likely to require an adaptive, multi-
pronged approach. While pooling of samples may not
be the most appropriate solution for very sensitive test-
ing, pooling may drastically improve our ability to screen
large populations while conserving limited testing
resources.
Lastly, it is important to consider that enzyme-based
tests are not always feasible in resource-limited scenarios.
One potential alternative lies in the use of DNA “nano-
switch”-based tests that have been developed for Zika vi-
rus detection. Based on a DNA origami design, these
nanoswitch DNA oligomers bind viral RNA to undergo a
conformational change that can be visualized on an aga-
rose gel. DNA nanoswitches targeting different species
of RNA viruses can also be combined in one test, allowing
for the detection of co-infections. Unfortunately, the Zika
nanoswitch test requires ∼5.2×105 Zika RNA genomes
per test for reliable detection and is thus far less sensitive
than RT-PCR (Zhou et al. 2020). Due to being a gel-based
method, the throughput of DNA nanoswitch tests is also
severely limited. To avoid low-throughput gel detection,
the Godin group developed a nanopore sensor capable
of detecting these conformational changes and could
detect as few as ∼500 target molecules (Beamish et al.
2019). Further innovation in DNA nanoswitch detection
of SARS-CoV-2 and developments in generating fluores-
cent or colorimetric outputs could significantly improve
the test’s throughput and facilitate its use for COVID-19
detection in low-resource areas.
OUTLOOK
In response to the tremendous global toll of COVID-19, re-
searchers have rapidly mobilized to investigate solutions
for testing, diagnosis, and treatment. Preprint and pub-
lished articles from the past several months describe a va-
riety of options for rapid, affordable, sensitive, and high-
throughput nucleic acid testing, which is currently the
most reliable approach for early detection of SARS-CoV-
2. To address the dire need for increased testing, research-
ers across disciplines have quickly compared widely avail-
able commercial products, proposed repurposing existing
reagents and infrastructure, and created novel laboratory
solutions to optimize the COVID-19 testing pipeline.
Academic researchers at a few institutions around the
world have published detailed blueprints for establishing
local pop-up testing centers, and others are likely to follow
(Aitken et al. 2020; Innovative Genomics Institute SARS-
CoV-2 Testing Consortium and Doudna 2020; Sridhar
et al. 2020). A combination of testing approaches may
be the most efficient way to fill the current gaps in testing.
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We are hopeful that the explosion of creative and multifac-
eted approaches to COVID-19 nucleic-acid testing will
continue to seed solutions as society addresses the
COVID-19 pandemic.
GLOSSARY
RT-PCR—reverse transcription polymerase chain reaction;
amplification of RNA in a one-step reaction containing a
reverse transcriptase enzyme, DNA polymerase, and a
specific primer complementary to a target region.
LAMP—loop-mediated isothermal amplification that
uses four primers that recognize six complementary re-
gions within the target. Amplification occurs from a
strand-displacing polymerase and elongation of primers
with self-complimentary regions for hairpins that prime fur-
ther rounds of amplification forming large “cauliflower”
structures of amplified products.
RPA—rapid amplification; recombinase polymerase am-
plification uses a recombinase-primer complex which finds
matches in the DNA or RNA template and enables strand
exchange to form an open complex. Single-stranded bind-
ing proteins stabilize the open duplex and strand-displac-
ing DNA polymerase amplifies the template.
RAMP—a two-stage isothermal amplification technique
combining a primary RPA reaction using the outside LAMP
primers with a secondary LAMP reaction including self-
complimentary internal primers.
Ct or Cq value—in qPCR, the amplification cycle where
the fluorescence curve exhibits the greatest curvature
and exceeds the background fluorescence threshold.
Sensitivity (Baratloo et al. 2015)—the ability of a
test to detect a true positive=
true positive
true positive+ false negative ∗ 100.
Specificity (Baratloo et al. 2015)—the ability of a
test to detect a true negative=
true negative
false positive+ true negative ∗ 100.
Accuracy (Baratloo et al. 2015)—the ability of a test to
differentiate true positive and negative results correctly
from the total tests =
true positive+ true negative
true positive+ false positive+ true negative+ false negative ∗ 100.
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